Your Expert Speakers
Speakers
Andrew Weinberg
President & Chief Scientific Officer
AgonOx
Day One
Tuesday 25th October 2022
8:30 am | Industry Leaders’ Fireside Chat – Accelerating the Potential of Adoptive T-Cell Therapy to Drive Toward Approved Cell Therapies in Solid Tumors: Discussing the Past, Present & Future for TIL
Day Two
Wednesday 26th October 2022
2:00 pm | Are Tumor-Reactive TIL Really Exhausted or Can They Be Rescued For Adoptive T cell Therapy: Clinical Implications
Daniel Powell
Assocaite Professor of Pathology & Laboratory Medicine
University of Pennsylvania
Day One
Tuesday 25th October 2022
12:00 pm | Methods for Enrichment of TIL with Autologous Tumor-Reactivity & Stem-Like Qualities
8:30 am | Industry Leaders’ Fireside Chat – Accelerating the Potential of Adoptive T-Cell Therapy to Drive Toward Approved Cell Therapies in Solid Tumors: Discussing the Past, Present & Future for TIL
Eduardo Davila
Professor & Director of Immunotherapy Medical Oncology
University of Colorado Comprehensive Cancer Center
Pre-Conference Day
Monday 24th October 2022
3:00 pm | Workshop C - Optimizing Cryopreservation to Support the Development of TIL Therapies
Friedrich Graf Finckenstein
Chief Medical Officer
Iovance Biotherapeutics
Day One
Tuesday 25th October 2022
8:30 am | Industry Leaders’ Fireside Chat – Accelerating the Potential of Adoptive T-Cell Therapy to Drive Toward Approved Cell Therapies in Solid Tumors: Discussing the Past, Present & Future for TIL
Ian Hardy
R&D Reagents
Miltenyi Biotec
Day One
Tuesday 25th October 2022
10:00 am | CliniMACS Prodigy TRT System: Streamlining TIL Manufacturing
Jan Meulen
Chief Scientific Officer
Obsidian Therapeutics
Day Two
Wednesday 26th October 2022
1:00 pm | Engineering an IL2-Free, Potent & Persistent TIL With Regulated Membrane-Bound IL15
Karrie Wong
Director of Cell Therapy
KSQ Therapeutics, Inc
Pre-Conference Day
Monday 24th October 2022
9:00 am | Workshop A - Developing an Analytical Genotoxicity Package: From Preclinical Development Through Drug Product Release & Beyond
Kumar Karyampudi
Director Cell Therapy Facility
Moffitt Cancer Center
Day Two
Wednesday 26th October 2022
9:00 am | Defining Critical Quality Attributes (CQAs) of TIL Products
Mark Dudley
Chief Scientific Officer
Instil Bio
Day One
Tuesday 25th October 2022
11:30 am | Developing a Novel Costimulatory Antigen Receptor With Dual CD28/ CD40 Signaling Domains to Improve Adoptive Cell Therapies
8:30 am | Industry Leaders’ Fireside Chat – Accelerating the Potential of Adoptive T-Cell Therapy to Drive Toward Approved Cell Therapies in Solid Tumors: Discussing the Past, Present & Future for TIL
Micah Benson
Senior Vice President
KSQ Therapeautics
Day Two
Wednesday 26th October 2022
12:00 pm | Rational Design of CRISPR/Cas9-engineered TIL Therapies
Michael Lotze
Chief Cell Therapy Officer
Nurix Therapeutics
Day One
Tuesday 25th October 2022
1:30 pm | Combining TIL with Small Molecule Inhibitors to Enhance T – Cell Expansion & Phenotypes
8:30 am | Industry Leaders’ Fireside Chat – Accelerating the Potential of Adoptive T-Cell Therapy to Drive Toward Approved Cell Therapies in Solid Tumors: Discussing the Past, Present & Future for TIL
Moran Meiron
Director of Advanced Therapies
Orgenesis Inc.
Day Two
Wednesday 26th October 2022
9:30 am | Decentralized Approach to Autologous Cell Therapy Manufacturing – Advantages of Harmonized TILs Manufacturing at a Point of Care
Nicholas Restifo
Stealth Explorer
Immunotherapy
Day One
Tuesday 25th October 2022
9:30 am | Enhancing Stemness of Polyclonal T Cells to Improve Anti-Tumor Activity
Peter Prieto
Assistant Professor
University of Rochester
Day One
Tuesday 25th October 2022
3:30 pm | Panel Discussion: Strategies & Approaches for Ensuring Clinical Success of TIL Therapies
Sergio Quezada
Chief Scientific Officer
Achilles Therapeutics Limited
Day Two
Wednesday 26th October 2022
10:00 am | Using AI-Powered Bioinformatics & Antigen Presenting Cells to Create a Measurable & Trackable Precision TIL Product Targeting Clonal Neoantigens
Simon Turcotte
Associate Professor of Surgery, T Cell Immunotherapy Program Lead
Université de Montréal
Day One
Tuesday 25th October 2022
3:30 pm | Panel Discussion: Strategies & Approaches for Ensuring Clinical Success of TIL Therapies
Pre-Conference Day
Monday 24th October 2022
12:00 pm | Workshop B - Cell Sorting to Manufacture TIL Products Enriched in Neoantigen-Reactive T Cells: What Are The Best Markers, Selection & Expansion Strategies?
Stephanie Woodall
Director - Head of Quality
KSQ Therapeautics
Pre-Conference Day
Monday 24th October 2022
9:00 am | Workshop A - Developing an Analytical Genotoxicity Package: From Preclinical Development Through Drug Product Release & Beyond
Sylvia Lee
Associate Professor, Program in Immunology Clinical Research Division
Fred Hutchinson Cancer Research Center (FHCRC)
Day One
Tuesday 25th October 2022
3:30 pm | Panel Discussion: Strategies & Approaches for Ensuring Clinical Success of TIL Therapies
Tom Henley
Chief Scientific Officer
Intima Bioscience
Day Two
Wednesday 26th October 2022
12:30 pm | Utilizing Multiplex CRISPR Gene Editing to Assess New Classes of Intra Cellular Immune Checkpoint Molecules for Application in TIL
Ulrik Cordes
Founder & Chief Executive Officer
Cbio
Day One
Tuesday 25th October 2022
2:00 pm | Next-Gen TIL Therapy With a Broader T-Cell Repertoire – The Key to Unlocking Less Immunogenic Solid Tumor Indications
